ABT-436
ABT-436 is a topic that has captured the attention of people around the world. From its discovery to its impact on society, this topic has been the subject of debate and discussion. Over the years, ABT-436 has evolved and influenced different aspects of everyday life. In this article, we will explore its importance and relevance today, as well as its possible implications for the future. Without a doubt, ABT-436 continues to be a topic of interest to academics, professionals and the general public, and it is essential to understand its scope and effects.
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| UNII | |
ABT-436 is an orally active, highly selective vasopressin V1B receptor antagonist which was under development by Abbott Laboratories and AbbVie for the treatment of major depressive disorder, anxiety disorders, and alcoholism but was discontinued.[1][2][3] It reached phase II clinical trials prior to the discontinuation of its development.[1][3]
See also
References
- ^ a b "ABT 436". AdisInsight. Springer Nature Switzerland AG.
- ^ Wernet W, Hornberger WB, Unger LV, Meyer AH, Netz PA, Oost T, et al. (2008). In vitro characterization of the selective vasopressin V1b receptor antagonists ABT-436 and ABT-558. Proceedings of Society for Neuroscience. Washington DC, USA. p. Abstract 560.
- ^ a b Ryan ML, Falk DE, Fertig JB, Rendenbach-Mueller B, Katz DA, Tracy KA, et al. (April 2017). "A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence". Neuropsychopharmacology. 42 (5): 1012–1023. doi:10.1038/npp.2016.214. PMC 5506792. PMID 27658483.
 | This hormonal preparation article is a stub. You can help Wikipedia by expanding it. |